Emerging anti-obesity agents (e.g., GLP- 1 receptor agonists, triple incretin agonists) show superior efficacy, necessitating formulation optimization for BBR to achieve clinical competitiveness. This evidence concerns the gene GLP1R and obesity due to melanocortin 4 receptor deficiency.